Literature DB >> 17065139

Late response to radiochemotherapy in pediatric glioblastoma: report on two patients treated according to HIT-GBM protocols.

C F Classen1, M Warmuth-Metz, K Papke, A Trotter, J E A Wolff, S Wagner.   

Abstract

High-grade gliomas in children are rare and the best treatment is undetermined. The German language group study HIT-GBM compares various induction protocols for subsequent patient cohorts. Currently, cisplatinum, etoposide, ifosfamide, and vincristine are given simultaneously with extended-field radiotherapy. Imaging is done 3 weeks after to define treatment response, followed by 6-weekly controls during consolidation with lomustine, vincristine, and prednisone. The authors report on 2 patients with incompletely resected glioblastoma multiforme in which response was lacking 3 weeks after radiochemotherapy but became evident 12 weeks later. This suggests that later time points are required to assess induction protocol response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065139     DOI: 10.1080/08880010600951088

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database.

Authors:  Birte Wolff; Ann Ng; Daniela Roth; Kathleen Parthey; Monika Warmuth-Metz; Matthias Eyrich; Uwe Kordes; Rolf Kortmann; Torsten Pietsch; Christof Kramm; Johannes Ea Wolff
Journal:  J Neurooncol       Date:  2011-10-01       Impact factor: 4.130

2.  High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.

Authors:  Johannes E Wolff; Rolf-Dieter Kortmann; Birte Wolff; Torsten Pietsch; Ove Peters; Hans-Joerg Schmid; Stefan Rutkowski; Monika Warmuth-Metz; Christoph Kramm
Journal:  J Neurooncol       Date:  2010-08-08       Impact factor: 4.130

3.  Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database.

Authors:  Johannes E A Wolff; Carl Friedrich Classen; Sabine Wagner; Rolf-Dieter Kortmann; Shana L Palla; Torsten Pietsch; Joachim Kühl; Astrid Gnekow; Christof M Kramm
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.